PACCALPan American Concerned Citizens Action League
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
"Paccal Vet-CA1 is the first veterinary drug to utilize paclitaxel, one of the most frequently used chemotherapeutics for the treatment of a wide range of cancers in humans for the past 20 years," says the manufacturer, Oasmia Pharmaceutical AB in Uppsala, Sweden.
Paccal Vet, which is being developed to treat cancer in dogs, is a combination of Oasmia's patented excipient XR-17 and chemotherapeutic substance paclitaxel.
The company said that based on an independent valuation by one of the big four accounting firms, the fair market value of the registered intellectual property relating to Oasmia's animal oncology products, Paccal Vet and Doxophos Vet, is assessed in the range of USD75m to USD80m, This independent valuation in a potential transaction could differ from the indicated range.
In addition, Oasmia has temporarily withdrawn its FDA approval for Paccal Vet in order to lower the dosage to reduce side effects and improve comfort for companion animals, before resubmitting for review.
The first is Paccal Vet, a patented formulation of the well-known substance paclitaxel and XR17.
Paccal Vet-CA1 has previously received conditional approval from the FDA for the treatment of non resectable stage III, IV or V mammary carcinoma in dogs that have not previously received chemotherapy or radiotherapy, as well as for the treatment of resectable and non resectable squamous cell carcinoma in dogs that have not received previous chemotherapy or radiotherapy in the US.
However, while know-how is transferred to Baxter, launch quantities of Paccal Vet will be manufactured by Oasmia in its plant in Uppsala, north of Stockholm.
31 August 2010 - Swedish company Oasmia Pharmaceutical AB (NGM: OASM A) said today it submitted the veterinary medicinal product dossier of its drug Paccal Vet for the treatment of mast cell tumours in dogs to be evaluated from the European Medicines Agency (EMA).
Paccal Vet is a novel formulation composed of Oasmia's patented excipient XR-17 and the anti-cancer substance paclitaxel.
21 October 2009 - Swedish company Oasmia Pharmaceutical AB (NGM: OASM A) said today it has completed the enrollment of 243 dogs in the pivotal field study aimed to determine the safety and efficacy of the veterinary oncology drug Paccal Vet.
This is a major milestone for Oasmia, since Paccal Vet is the first parenteral cytotoxic drug being examined to treat malignant skin cancer in dogs, the company said.